Physician profile
Thomas Schorr
NPI 1679066914
$1,181.27
in general payments reported to CMS, 2019-2025
22 companies · $18.83 in 2025
The $18.83 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $176 · 2023: $456 · 2024: $530 · 2025: $18.83.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,005.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,005.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $194.20 | 2022-2024 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $181.51 | 2022-2024 | |
| Lilly USA, LLC | $153.75 | 2022-2024 | Jardiance, Mounjaro, Zepbound |
| Dexcom, INC. | $72.11 | 2022-2024 | Dexcom G6 Transmitter |
| Abbott Laboratories | $65.85 | 2024-2025 | Freestyle Libre 3 |
| Mylan Specialty L.P. | $61.99 | 2022-2024 | Yupelri |
| Exact Sciences Corporation | $50.05 | 2024 | Cologuard Collection Kit |
| Dynavax Technologies Corporation | $44.99 | 2022-2024 | Heplisav-B |
| Pfizer INC. | $42.41 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $41.32 | 2023-2024 | Farxiga, Breztri |
| Merck Sharp & Dohme LLC | $39.36 | 2023-2024 | Gardasil 9, Vaxelis, Gardasil |
| Glaxosmithkline, LLC. | $33.66 | 2023-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Inspire Medical Systems, INC. | $29.70 | 2024 | Inspire |
| Takeda Pharmaceuticals U.S.A., INC. | $28.97 | 2023-2024 | Trintellix |
| Medtronic, INC. | $20.81 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $19.66 | 2022 | |
| Ironshore Pharmaceuticals INC. | $19.11 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.50 | 2024 | |
| Lucid Diagnostics INC. | $16.81 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.49 | 2023 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.24 | 2023 | Jardiance |
| Cranial Technologies, INC | $13.78 | 2023 | Doc Band |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Schorr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.